Remove Ablation Remove AFIB Remove Myocardial Infarction
article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

The VARIPULSE Platform is comprised of the VARIPULSE Catheter, a fully integrated variable-loop multielectrode catheter; the TRUPULSE Generator, a pulsed field ablation (PFA) generator; and the CARTO 3 System VARIPULSE Software, which provides full integration with the world's leading 3D cardiac mapping system.

article thumbnail

Supercharging the ECG: AI set to Revolutionize the Diagnostic Cardiology Market

DAIC

Within the last six months, separate AI-ECG algorithms for detecting Low Ejection Fraction (Anumana), Hypertrophic cardiomyopathy (Viz.ai), and Occlusion Myocardial infarction (Powerful Medical) have all been granted regulatory clearance (the latter under the EU MDR) and are in the early stages of deployment.

AFIB 105
article thumbnail

Cardiovascular Updates from AHA Congress 2024 

Cardiometabolic Health Congress

OPTION Trial : LAAC after AFib ablation was associated with lower risks of major bleeding compared to oral anticoagulation. VANISH2 Trial : Catheter ablation as first-line therapy reduced VT episodes more effectively than antiarrhythmic drugs in ischemic cardiomyopathy patients. Access the full study. View the study.

CME 52
article thumbnail

ACC/AHA Release Updated 2023 Guidelines for Atrial Fibrillation

Cardiometabolic Health Congress

Furthermore, it includes the latest recommendations which specifically address AF and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, AF catheter or surgical ablation, and risk factor modification and AF prevention. As such, the Class of Recommendation for catheter ablation has been upgraded.